Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asger Lund

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Diabetes, Obesity & Metabolism|October 7, 2021
Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetesNicklas J Johansen, Thomas F Dejgaard, Asger Lund, et al.
Diabetes Care|March 23, 2022
Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover TrialCasper K Nielsen, Caroline C Øhrstrøm, Urd L Kielgast, et al.
JHEP Reports : Innovation in Hepatology|June 25, 2021
Hepatic microbiome in healthy lean and obese humansMalte Palm Suppli, Jonatan Ising Bagger, Benjamin Lelouvier, et al.
Diabetes Care|September 13, 2023
Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover StudyMille Baekdal, Sophie W Nielsen, Carsten P Hansen, et al.
Diabetes, Obesity & Metabolism|April 15, 2018
Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?Emilie S Andersen, Asger Lund, Jonatan I Bagger, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2019
Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without DiabetesNatasha Chidekel Bergmann, Asger Lund, Lærke Smidt Gasbjerg, et al.
Endocrine Connections|November 10, 2023
Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver diseaseIben Rix, Marie L Johansen, Asger Lund, et al.
Diabetes|December 27, 2021
Glucagon Clearance is Preserved in Type 2 DiabetesMagnus F G Grøndahl, Asger Lund, Jonatan I Bagger, et al.
Diabetes|October 27, 2021
Glucagon Clearance is Preserved in Type 2 DiabetesMagnus F G Grøndahl, Asger Lund, Jonatan I Bagger, et al.
European Journal of Endocrinology|December 4, 2021
The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetesSofie Hædersdal, Asger Lund, Henrik Maagensen, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Diabetes, Obesity & Metabolism|October 7, 2021
Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetesNicklas J Johansen, Thomas F Dejgaard, Asger Lund, et al.
Diabetes Care|March 23, 2022
Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover TrialCasper K Nielsen, Caroline C Øhrstrøm, Urd L Kielgast, et al.
JHEP Reports : Innovation in Hepatology|June 25, 2021
Hepatic microbiome in healthy lean and obese humansMalte Palm Suppli, Jonatan Ising Bagger, Benjamin Lelouvier, et al.
Diabetes Care|September 13, 2023
Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover StudyMille Baekdal, Sophie W Nielsen, Carsten P Hansen, et al.
Diabetes, Obesity & Metabolism|April 15, 2018
Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?Emilie S Andersen, Asger Lund, Jonatan I Bagger, et al.
The Journal of Clinical Endocrinology and Metabolism|March 9, 2019
Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without DiabetesNatasha Chidekel Bergmann, Asger Lund, Lærke Smidt Gasbjerg, et al.
Endocrine Connections|November 10, 2023
Hyperglucagonaemia and amino acid alterations in individuals with type 2 diabetes and non-alcoholic fatty liver diseaseIben Rix, Marie L Johansen, Asger Lund, et al.
Diabetes|December 27, 2021
Glucagon Clearance is Preserved in Type 2 DiabetesMagnus F G Grøndahl, Asger Lund, Jonatan I Bagger, et al.
Diabetes|October 27, 2021
Glucagon Clearance is Preserved in Type 2 DiabetesMagnus F G Grøndahl, Asger Lund, Jonatan I Bagger, et al.
European Journal of Endocrinology|December 4, 2021
The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetesSofie Hædersdal, Asger Lund, Henrik Maagensen, et al.
Pageof 6